PCRX
Pacira Pharmaceuticals Inc
Healthcare, Event Driven/Special Sit
08/04/2015
Presented
| Date | 07/31/2015 |
| Price | $66.42 |
| Market Cap | $2.77B |
| Ent Value | $3.66B |
| P/E Ratio | N/A |
| Book Value | $5.06 |
| Div Yield | 0% |
| Shares O/S | 41.78M |
| Ave Daily Vol | 761,833 |
| Short Int | 14.30% |
Current
| Price | $16.69 |
| Market Cap | $0.77B |
| Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. It develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company markets EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic, indicated for administration into the surgical site to produce postsurgical analgesia; and DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a cancer of the immune system. Its product pipeline comprise EXPAREL that has completed Phase II clinical trials for postsurgical analgesia-nerve block administration; DepoNSAID, which is in preclinical trials for the relief of that is in preclinical trials acute pain; and DepoMethotrexate for the treatment of rheumatoid arthritis and oncology, as well as Bupivacaine Liposome Injectable Suspension for veterinary postsurgical analgesia. Pacira Pharmaceuticals was founded in December 2006 and is headquartered in Parsippany, NJ. |
Publicly traded companies mentioned herein: Endo International Plc (ENDP), Mallinckrodt PLC (MNK), Pacira Pharmaceuticals Inc (PCRX), Tenet Healthcare Corp (THC), Teva Pharmaceutical Industries Ltd (TEVA)
Highlights
Pacira Pharmaceuticals (PCRX) manufacturers Exparel (liposomal bupivacaine), an approved, non-opioid injectable for post-operative pain management. The presenter is long the stock and thinks the recent weakness is a buying opportunity (shares are trading in the mid-$60s following the 2Q earnings call but traded as high as $120 over the past year). For the three years following the launch of Exparel, PCRX could do almost no wrong. The company executed one of the best hospital launches in history only to run into “a series of problems over the past six months, including receiving a complete response letter from the FDA that has caused delays in obtaining a nerve block indication, and the DOJ investigating its marketing practices after settling with the FDA on the same issue (February, 2015)”. If PCRX can work through its issues and start to grow revenue again, the presenter thinks it is likely to be targeted by an acquirer and/ or the stock will trade up to the $140 - $150 range.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.